EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non–Small Cell Lung Cancer

Autor:	Roxana Reyes, Mireia García, Cristina Teixido, Francisco M. Pérez, Roberto Martin-Deleon, Pedro Jares, Naiara Vega, Daniel Martinez, Ramón Mª Marrades, Carlos Agustí, Elba Marin, Ivan Vollmer, Noemi Reguart, Ainhoa Fontana, Nuria Viñolas, Marcelo Sánchez, Carmen M. Lucena
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Ebus tbna Oncology PD-L1 Cancer Research medicine.medical_specialty Concordance NSCLC Article 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy medicine Lung cancer Genotyping Reference standards RC254-282 medicine.diagnostic_test business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030228 respiratory system 030220 oncology & carcinogenesis nCounter NGS EBUS cytology Immunohistochemistry Non small cell business
Zdroj:	Cancers Volume 13 Issue 9 Cancers, Vol 13, Iss 2084, p 2084 (2021)
ISSN:	2072-6694
DOI:	10.3390/cancers13092084
Popis:	Clinical guidelines promote the identification of several targetable biomarkers to drive treatment decisions in advanced non-small cell lung cancer (NSCLC), but half of all patients do not have a viable biopsy. Specimens from endobronchial-ultrasound transbronchial needle aspiration (EBUS-TBNA) are an alternative source of material for the initial diagnosis of NSCLC, however their usefulness for a complete molecular characterization remains controversial. EBUS-TBNA samples were prospectively tested for several biomarkers by next-generation sequencing (NGS), nCounter, and immunohistochemistry (PD-L1). The primary objectives were to assess the sensitivity of EBUS-TBNA samples for a comprehensive molecular characterization and to compare its performance to the reference standard of biopsy samples. Seventy-two EBUS-TBNA procedures were performed, and 42 NSCLC patients were diagnosed. Among all cytological samples, 92.9% were successfully genotyped by NGS, 95.2% by nCounter, and 100% by immunohistochemistry. There were 29 paired biopsy samples 79.3% samples had enough tumor material for genomic genotyping, and 96.6% for PD-L1 immunohistochemistry. A good concordance was found between both sources of material: 88.9% for PD-L1, 100% for NGS and nCounter. EBUS-TBNA is a feasible alternative source of material for NSCLC genotyping and allows the identification of patient candidates for personalized therapies with high concordance when compared with biopsy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1c669670bdd57b26275bf15781cfd5 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.